These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37843374)

  • 41. A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency.
    Tordo J; O'Leary C; Antunes ASLM; Palomar N; Aldrin-Kirk P; Basche M; Bennett A; D'Souza Z; Gleitz H; Godwin A; Holley RJ; Parker H; Liao AY; Rouse P; Youshani AS; Dridi L; Martins C; Levade T; Stacey KB; Davis DM; Dyer A; Clément N; Björklund T; Ali RR; Agbandje-McKenna M; Rahim AA; Pshezhetsky A; Waddington SN; Linden RM; Bigger BW; Henckaerts E
    Brain; 2018 Jul; 141(7):2014-2031. PubMed ID: 29788236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tracking Adeno-Associated Virus Capsid Evolution by High-Throughput Sequencing.
    de Alencastro G; Pekrun K; Valdmanis P; Tiffany M; Xu J; Kay MA
    Hum Gene Ther; 2020 May; 31(9-10):553-564. PubMed ID: 32024384
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants.
    Rapti K; Maiakovska O; Becker J; Szumska J; Zayas M; Bubeck F; Liu J; Gerstmann E; Krämer C; Wiedtke E; Grimm D
    J Vis Exp; 2022 Oct; (188):. PubMed ID: 36342179
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural and antigenic characterization of the avian adeno-associated virus capsid.
    Hsi J; Mietzsch M; Chipman P; Afione S; Zeher A; Huang R; Chiorini J; McKenna R
    J Virol; 2023 Oct; 97(10):e0078023. PubMed ID: 37702486
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AAV capsid design: A Goldilocks challenge.
    Zolotukhin S; Vandenberghe LH
    Trends Mol Med; 2022 Mar; 28(3):183-193. PubMed ID: 35093287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid.
    Timmers AM; Newmark JA; Turunen HT; Farivar T; Liu J; Song C; Ye GJ; Pennock S; Gaskin C; Knop DR; Shearman MS
    Hum Gene Ther; 2020 Jan; 31(1-2):80-89. PubMed ID: 31544533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism.
    Muzyczka N; Warrington KH
    Hum Gene Ther; 2005 Apr; 16(4):408-16. PubMed ID: 15871672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling.
    Kienle E; Senís E; Börner K; Niopek D; Wiedtke E; Grosse S; Grimm D
    J Vis Exp; 2012 Apr; (62):. PubMed ID: 22491297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New recombinant serotypes of AAV vectors.
    Gao G; Vandenberghe LH; Wilson JM
    Curr Gene Ther; 2005 Jun; 5(3):285-97. PubMed ID: 15975006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Engineering AAV receptor footprints for gene therapy.
    Madigan VJ; Asokan A
    Curr Opin Virol; 2016 Jun; 18():89-96. PubMed ID: 27262111
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GPR108 Is a Highly Conserved AAV Entry Factor.
    Dudek AM; Zabaleta N; Zinn E; Pillay S; Zengel J; Porter C; Franceschini JS; Estelien R; Carette JE; Zhou GL; Vandenberghe LH
    Mol Ther; 2020 Feb; 28(2):367-381. PubMed ID: 31784416
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy.
    Liu Y; Siriwon N; Rohrs JA; Wang P
    Curr Pharm Des; 2015; 21(22):3248-56. PubMed ID: 26027561
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of Broadly Applicable Adeno-Associated Virus Vectors by Systematic Comparison of Commonly Used Capsid Variants
    Weinmann J; Söllner J; Abele S; Zimmermann G; Zuckschwerdt K; Mayer C; Danner-Liskus J; Peltzer A; Schuler M; Lamla T; Strobel B
    Hum Gene Ther; 2022 Nov; 33(21-22):1197-1212. PubMed ID: 36097758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of AAV Serotypes 4, 5, and 11.
    Earley LF; Powers JM; Adachi K; Baumgart JT; Meyer NL; Xie Q; Chapman MS; Nakai H
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852862
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism.
    Powell SK; Khan N; Parker CL; Samulski RJ; Matsushima G; Gray SJ; McCown TJ
    Gene Ther; 2016 Nov; 23(11):807-814. PubMed ID: 27628693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimization of AAV vectors to target persistent viral reservoirs.
    Colón-Thillet R; Jerome KR; Stone D
    Virol J; 2021 Apr; 18(1):85. PubMed ID: 33892762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.
    Saraiva J; Nobre RJ; Pereira de Almeida L
    J Control Release; 2016 Nov; 241():94-109. PubMed ID: 27637390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.